Remote Control Monitoring For Medical Devices Trending In COVID-19 For Non-Invasive Treatment; Electromedical Technologies, Inc. (OTCQB: EMED) Leads As EMED’s WellnessPlus POD With Remote Monitoring Portal Will Provide Relief From Chronic And Acute Pain


Remote control and non-invasive medical device treatment is trending in COVID-19 and Electromedical Technologies, Inc.’s (OTCQB: EMED) highly anticipated WellnessPlus POD is designed to deliver relief from chronic and acute pain with a non-invasive remote monitoring portal. A new Goldman Small Cap Research report projects EMED conservatively to reach $17 million in volume by 2022, and perhaps as high as $22 million with unit sales of its devices that year reaching 80,000 or 90,000 units.

The chronic pain treatment market has drawn intense interest from media companies. features specialized coverage of related stocks such as Electromedical Technologies, Inc. (OTCQB: EMED), Medtronic PLC (NYSE: MDT),  Nevro Corp. (NYSE: NVRO), Axsome Therapeutics, Inc. (NASDAQ: AXSM).  GlaxoSmithKline (NYSE: GSK),  Abbott Laboratories (NYSE: TBA), Eli Lilly (NYSE: LLY),  Boston Scientific Corporation (NYSE: BSX), Novartis AG (NYSE: NVS), Johnson & Johnson (NYSE: JNJ) and Bristol-Myers Squibb (NYSE: BMY).

Remote Control  Monitoring For Medical Devices Trending In COVID-19 For Non-Invasive Treatment; Electromedical Technologies, Inc. (OTCQB: EMED) Leads As EMED’s WellnessPlus POD With Remote Monitoring Portal Will Provide Relief From Chronic And Acute Pain

Goldman Small Cap Research projected EMED’s FDA cleared WellnessPro Plus device will exponentially grow in sales. The analysis is most optimistic about the sales of the to-be-introduced in late 2021 after an anticipated FDA clearance of the WellnessPlus POD with a remote monitoring portal. The telemedicine-like remote portal will enable physicians and technicians to monitor in real time a remote view of therapy effectiveness — a trend as medical facilities are stressed due to COVID-19. The FDA has just issued emergency use authorizations for remote devices.

Remote Control Treatment Monitoring Trending In Medical Field

The remote control monitored hospital ward may sound like something out of this world — but it is becoming a reality quicker due to the overwhelming needs of COVID-19 patients. For non-invasive devices, and a lack of qualified physicians and technicians. Dr. Julian Goldman, an anesthesiologist at Massachusetts General Hospital (MGH), said, “We started when a demand for inexpensive ventilators created what was basically a ‘Wild West’ of innovation Since then, the situation has evolved.”He said devices with remote control capabilities are needed — and are being designed.”

Certain remote or patient-wearing monitoring devices may act as a ‘auxiliary human machine interface’ enabling physicians and caretakers to operate a medical device from a location not co-located with the patient, device or its primary interface. The strain of COVID-19 requires medical innovation and remote monitoring. Enter the advances of Electromedical Technologies, Inc.’s (OTCQB: EMED) WellnessPlus POD With Remote Monitoring Portal. It is non-invasive, designed for remote treatment and providing relief from chronic and acute pain. It is also successful with its FDA cleared Wellness Pro Plus devices.

Telemedicine Accelerated By COVID-19 Into Greater Demand For More Remote Monitoring Devices

In medical fields ranging from treatment of health and wellness and mental health, the use of remote monitoring devices enables medical facilities to provide treatments for patients and offer real time monitoring by medical providers. Remote Control  Monitoring For Medical Devices Trending I COVID-19 For Non-Invasive Treatment; Electromedical Technologies, Inc. (OTCQB: EMED) Leads As EMED’s WellnessPlus POD With Remote Monitoring Portal Will Provide Relief From Chronic And Acute Pain.

Projected Volume For EMED In 2022 Could Be $17-$22 Million: Goldman Report

The Goldman report projects that Electromedical Technologies, Inc. (OTCQB: EMED) could sell up to 80,000-90,000 units in 2022 with a premium portal feature that could provide remote monitoring of patient treatment and drive 2022 volume as high as $22 million. The goal is to use treatment from the non-invasive devices to evade the $24 billion possibly-addicting opioids pain killer drug market. Medical institutions are looking to alternative therapies to relive chronic and acute pain that do not contain prescription drugs, which have the side effect of addiction to opioids. It is estimated that the opioid prescription market is $24 billion with 300 million prescriptions for pain killing drugs written annually, the Report said.

Bioelectronics Blocks Nerve Signals Naturally

Bioelectronics blocks nerve signals naturally, far preferred to prescription pharmaceuticals that can have the harmful side effect of opioid addiction. Bioelectronics manipulate  the body’s nervous system to ignore pain and activate the body’s natural pain killers. Anticipating the on-boarding of hundreds of new medical practitioners and distributors, EMED is building up inventory of the devices as it transitions into 2021.

Remote Monitoring Portal Feature In POD Model Is Seen As Driving Booming Sales

The company has a combination purchase down payment/subscription payment revenue model which provides recurring revenue for sales of its devices. The upbeat forecast by Goldman SmallCap Research is largely based on prior sales of the FDA cleared Wellness Pro Plus device and forecast of the success of WellnessPlus POD. Analyst Rob Goldman was especially impressed with its telemedicine-like portal feature that permits physicians or technicians to monitor in real time how the wearable POD therapy is delivering relief from acute and chronic pain.

EMED Offers Devices Which Are Alternative To Opioid Addicting Pain Killer Drugs

Electromedical Technologies, Inc. (OTCQB: EMED has successfully marketed its non-invasive FDA-cleared WellnessPro Plus™ as an alternative treatment to opioid pain killer pharmaceuticals which can be addictive. Remote Control  Monitoring For Medical Devices Trending In COVID-19 For Non-Invasive Treatment; Electromedical Technologies, Inc. (OTCQB: EMED) Leads As EMED’s WellnessPlus POD With Remote Monitoring Portal Will Provide Relief From Chronic And Acute Pain.

Inventory Build Up As  Electromedical Technologies, Inc. (OTCQB: EMED) Anticipates More Demand In 2021

For 2021, Matthew Wolfson, CEO, believes that patients who have experienced chronic pain relief from the bioelectronics and electro-modulation delivered by the Wellness Pro Plus devices warrant the investment in the year-end inventory build-up. In anticipation of a rush for the product in early 2021, the company has invested $4.2 Million as it has built and paid for a 1,200+ unit inventory in preparation for attracting hundreds more medical practitioners and distributors in 2021.

Goldman Small Cap Research Last Week Set A $5.70 12-Month Price Target For Electromedical Technologies, Inc. (OTCQB: EMED)

Goldman Small Cap Research last week set a $5.70 12-Month Price Target For Electromedical Technologies, Inc. (OTCQB: EMED), in an Opportunity Research report. The investment analysis projects that the medical device company will reach a volume of  $17+ Million in FY2022 and projects EMED will sell some 80,000-90,000 devices in 2022. But both the projected volume and units sold could be even higher.

The WellnessPlus Pod Seen Debuting In Late 2021, After Anticipated FDA Clearance

Electromedical Technologies, Inc. (OTCQB: EMED) will debut in late 2021 the WellnessPlus POD, a smaller, professional, less costly device that features a special  portal for telemedicine-like real time monitoring by physicians. The WellnessPro POD links doctors/technicians and patients with that feature and is less costly, smaller, portable and offers a remote POD portal. The device also provides a unique financial sales structure for the Company, combining a down payment purchase with a recurring monthly subscription services fee.

Source: Stock Market Press

Join Stock Market Press’ newsletter for the latest in IPO, market commentary and company profiles.

Stock Market Press is a financial news company that delivers up to date stock news, introduces private and public companies to a wide audience of investors, consumers, journalists and the general public via social media and a rapidly expanding network.


Stock Market Press
110 Wall St.
New York, NY 10005 Safe Harbor Statement:

Statements in this news release may be ”forward-looking statements.” Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release and Stock Market Press undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release.

See Stock Market Press disclaimer: SOURCE: Stock Market Press